Literature DB >> 25385636

Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K).

Yoshihiro Ito1, Jonathan R Hart1, Lynn Ueno1, Peter K Vogt2.   

Abstract

Expression of the regulatory subunit p85β of PI3K induces oncogenic transformation of primary avian fibroblasts. The transformed cells proliferate at an increased rate compared with nontransformed controls and show elevated levels of PI3K signaling. The oncogenic activity of p85β requires an active PI3K-TOR signaling cascade and is mediated by the p110α and p110β isoforms of the PI3K catalytic subunit. The data suggest that p85β is a less effective inhibitor of the PI3K catalytic subunit than p85α and that this reduced level of p110 inhibition accounts for the oncogenic activity of p85β.

Entities:  

Keywords:  SH2 domain; inter-SH2 domain; protein–protein interaction

Mesh:

Substances:

Year:  2014        PMID: 25385636      PMCID: PMC4250105          DOI: 10.1073/pnas.1420281111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch.

Authors:  Zheng Fu; Eliah Aronoff-Spencer; Haiyan Wu; Gary J Gerfen; Jonathan M Backer
Journal:  Arch Biochem Biophys       Date:  2004-12-15       Impact factor: 4.013

2.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.

Authors:  J Yu; C Wjasow; J M Backer
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

3.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

4.  A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis.

Authors:  Zaira García; Virginia Silio; Miriam Marqués; Isabel Cortés; Amit Kumar; Carmen Hernandez; Ana I Checa; Antonio Serrano; Ana C Carrera
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

5.  PI 3-kinase p110beta: a new target for antithrombotic therapy.

Authors:  Shaun P Jackson; Simone M Schoenwaelder; Isaac Goncalves; Warwick S Nesbitt; Cindy L Yap; Christine E Wright; Vijaya Kenche; Karen E Anderson; Sacha M Dopheide; Yuping Yuan; Sharelle A Sturgeon; Hishani Prabaharan; Philip E Thompson; Gregg D Smith; Peter R Shepherd; Nathalie Daniele; Suhasini Kulkarni; Belinda Abbott; Dilek Saylik; Catherine Jones; Lucy Lu; Simon Giuliano; Sascha C Hughan; James A Angus; Alan D Robertson; Hatem H Salem
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

6.  Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.

Authors:  Saskia M Brachmann; Claudine M Yballe; Metello Innocenti; Jonathan A Deane; David A Fruman; Sheila M Thomas; Lewis C Cantley
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

7.  Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism.

Authors:  Xuxiao Zhang; Oscar Vadas; Olga Perisic; Karen E Anderson; Jonathan Clark; Phillip T Hawkins; Len R Stephens; Roger L Williams
Journal:  Mol Cell       Date:  2011-03-04       Impact factor: 17.970

8.  Expression and characterization of the p85 subunit of the phosphatidylinositol 3-kinase complex and a related p85 beta protein by using the baculovirus expression system.

Authors:  I Gout; R Dhand; G Panayotou; M J Fry; I Hiles; M Otsu; M D Waterfield
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

9.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Authors:  Adrian J Folkes; Khatereh Ahmadi; Wendy K Alderton; Sonia Alix; Stewart J Baker; Gary Box; Irina S Chuckowree; Paul A Clarke; Paul Depledge; Suzanne A Eccles; Lori S Friedman; Angela Hayes; Timothy C Hancox; Arumugam Kugendradas; Letitia Lensun; Pauline Moore; Alan G Olivero; Jodie Pang; Sonal Patel; Giles H Pergl-Wilson; Florence I Raynaud; Anthony Robson; Nahid Saghir; Laurent Salphati; Sukhjit Sohal; Mark H Ultsch; Melanie Valenti; Heidi J A Wallweber; Nan Chi Wan; Christian Wiesmann; Paul Workman; Alexander Zhyvoloup; Marketa J Zvelebil; Stephen J Shuttleworth
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

10.  Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.

Authors:  Yoshimasa Saito; Jeffrey M Friedman; Yoshitomo Chihara; Gerda Egger; Jody C Chuang; Gangning Liang
Journal:  Biochem Biophys Res Commun       Date:  2008-12-29       Impact factor: 3.322

View more
  16 in total

1.  The structural basis for Ras activation of PI3Kα lipid kinase.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2019-06-05       Impact factor: 3.676

2.  A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.

Authors:  Sai Krishna Athuluri-Divakar; Rodrigo Vasquez-Del Carpio; Kaushik Dutta; Stacey J Baker; Stephen C Cosenza; Indranil Basu; Yogesh K Gupta; M V Ramana Reddy; Lynn Ueno; Jonathan R Hart; Peter K Vogt; David Mulholland; Chandan Guha; Aneel K Aggarwal; E Premkumar Reddy
Journal:  Cell       Date:  2016-04-21       Impact factor: 41.582

3.  Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation.

Authors:  C F de la Cruz-Herrera; M Baz-Martínez; V Lang; A El Motiam; J Barbazán; R Couceiro; M Abal; A Vidal; M Esteban; C Muñoz-Fontela; A Nieto; M S Rodríguez; M Collado; C Rivas
Journal:  Oncogene       Date:  2015-09-28       Impact factor: 9.867

4.  Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.

Authors:  Mingzhen Zhang; Zhigang Li; Guanqiao Wang; Hyunbum Jang; David B Sacks; Jian Zhang; Vadim Gaponenko; Ruth Nussinov
Journal:  J Phys Chem B       Date:  2018-08-08       Impact factor: 2.991

Review 5.  Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets.

Authors:  Yoshihiro Ito; Jonathan R Hart; Peter K Vogt
Journal:  Expert Opin Ther Targets       Date:  2018-09-24       Impact factor: 6.902

6.  Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.

Authors:  Yoshihiro Ito; Peter K Vogt; Jonathan R Hart
Journal:  Oncotarget       Date:  2017-08-03

7.  MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway.

Authors:  Yuan Qu; Jing Wu; Jia-Xin Deng; Yu-Ping Zhang; Wan-Yi Liang; Zhen-Lan Jiang; Qing-Hong Yu; Juan Li
Journal:  Oncotarget       Date:  2016-11-08

8.  LncRNA AK023948 is a positive regulator of AKT.

Authors:  Pratirodh Koirala; Jianguo Huang; Tsui-Ting Ho; Fangting Wu; Xianfeng Ding; Yin-Yuan Mo
Journal:  Nat Commun       Date:  2017-02-08       Impact factor: 14.919

9.  The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.

Authors:  Daphne Guinn; Amy Lehman; Catherine Fabian; Lianbo Yu; Kami Maddocks; Leslie A Andritsos; Jeffrey A Jones; Joseph M Flynn; Samantha M Jaglowski; Jennifer A Woyach; John C Byrd; Amy J Johnson
Journal:  Cancer Med       Date:  2017-03-15       Impact factor: 4.452

10.  Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.

Authors:  Jesús Vallejo-Díaz; Manuel Olazabal-Morán; Ariel E Cariaga-Martínez; María J Pajares; Juana M Flores; Ruben Pio; Luis M Montuenga; Ana Clara Carrera
Journal:  Oncotarget       Date:  2016-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.